` RVU (Ryvu Therapeutics SA) vs WIG20 Comparison - Alpha Spread

R
RVU
vs
W
WIG20

Over the past 12 months, RVU has underperformed WIG20, delivering a return of -4% compared to the WIG20's +28% growth.

Stocks Performance
RVU vs WIG20

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
RVU vs WIG20

Performance Gap Between RVU and WIG20
HIDDEN
Show

Performance By Year
RVU vs WIG20

Loading
RVU
WIG20
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Ryvu Therapeutics SA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Ryvu Therapeutics SA
Glance View

Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 186 full-time employees. The company went IPO on 2011-07-14. The firm is active in the pharmaceutical and biotechnology fields. The company operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. The company operates through unit Ardigen SA and SORS Holdings Ltd.

RVU Intrinsic Value
HIDDEN
Show
Back to Top